TR200200146T2 - Prostaglandin E1 dağıtımı için topikal bileşimler - Google Patents

Prostaglandin E1 dağıtımı için topikal bileşimler

Info

Publication number
TR200200146T2
TR200200146T2 TR2002/00146T TR200200146T TR200200146T2 TR 200200146 T2 TR200200146 T2 TR 200200146T2 TR 2002/00146 T TR2002/00146 T TR 2002/00146T TR 200200146 T TR200200146 T TR 200200146T TR 200200146 T2 TR200200146 T2 TR 200200146T2
Authority
TR
Turkey
Prior art keywords
prostaglandin
composition
population
aliphatic
mixture
Prior art date
Application number
TR2002/00146T
Other languages
English (en)
Inventor
L. Yeager James
B�Y�Kt�Mk�N Nad�R
B�Y�Kt�Mk�N Servet
Original Assignee
Nexmed Holdings, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexmed Holdings, Inc. filed Critical Nexmed Holdings, Inc.
Publication of TR200200146T2 publication Critical patent/TR200200146T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Prostaglandin E1' in transdermal uygulanmasi için bir topikal ilaç üretiminde kullanilmak üzere, bir yari-kati kivama sahip bir bilesim verilmektedir. Bu bilesim sunlari içerir: Prostaglandin E1, bir nüfus arttirici, bir polisakkarit reçine, bir lipofilik bilesik ve bir asidik tampon sistem. Nüfus arttirici bir alkil-2-(N, N-disubstitüe amino) alkanoat ester, bir (N, Ndisubstitüe amino)- alkanol alkanoat ya da bunlarin karisimidir. Lipofilik bilesik, bir alifatik C1-C8 alkol, bir alifatik C8-C30 ester ya da bunlarin bir karisimidir. Bu bilesim, söz konusu bilesim için 3 ila 7.4 arasinda bir tampon pH degeri saglayan bir tampon sistem içermektedir. Bu bilesim erkekte sertlesme fonksiyon bozuklugu, kadin cinsel fonksiyon bozuklugu ve çevresel damar hastaliklarinin tedavisi için ilaç üretiminde yararlidir.
TR2002/00146T 1997-11-05 1999-05-13 Prostaglandin E1 dağıtımı için topikal bileşimler TR200200146T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/964,509 US6046244A (en) 1997-11-05 1997-11-05 Topical compositions for prostaglandin E1 delivery
PCT/US1999/010596 WO2000069469A1 (en) 1997-11-05 1999-05-13 Topical compositions for prostaglandin e1 delivery

Publications (1)

Publication Number Publication Date
TR200200146T2 true TR200200146T2 (tr) 2002-06-21

Family

ID=25508632

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2000/02158T TR200002158T2 (tr) 1997-11-05 1998-11-05 Prostaglandin E1'i ulaştırmak için topik terkipler
TR2002/00146T TR200200146T2 (tr) 1997-11-05 1999-05-13 Prostaglandin E1 dağıtımı için topikal bileşimler

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2000/02158T TR200002158T2 (tr) 1997-11-05 1998-11-05 Prostaglandin E1'i ulaştırmak için topik terkipler

Country Status (20)

Country Link
US (1) US6046244A (tr)
EP (2) EP1028708B1 (tr)
JP (2) JP4491560B2 (tr)
KR (2) KR100576986B1 (tr)
CN (2) CN1191060C (tr)
AT (2) ATE455535T1 (tr)
AU (1) AU757086B2 (tr)
BR (2) BR9813945A (tr)
CA (2) CA2309165A1 (tr)
DE (2) DE69841463D1 (tr)
DK (2) DK1028708T3 (tr)
ES (2) ES2338389T3 (tr)
HK (1) HK1044289B (tr)
HU (1) HU230300B1 (tr)
IL (3) IL135914A0 (tr)
MX (1) MXPA01011560A (tr)
PT (1) PT1178833E (tr)
TR (2) TR200002158T2 (tr)
TW (1) TW443933B (tr)
WO (2) WO1999022714A1 (tr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1002847B (el) 1997-05-06 1998-01-27 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US7629384B2 (en) 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US6414028B1 (en) * 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
GR1003199B (el) * 1998-08-14 1999-09-01 Χρηση της μισοπροστολης ή και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση της σεξουαλικης δυσλειτουργιας στις γυναικες
US6486207B2 (en) * 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6825234B2 (en) * 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US20070191320A1 (en) * 1998-12-10 2007-08-16 Nexmed Holdings, Inc. Methods of treatment for female sexual arousal disorder
EA008720B1 (ru) * 1998-12-10 2007-06-29 Нексмед (Холдингс), Инк. Применение композиции на основе простагландина для лечения расстройства сексуального возбуждения у женщин
US20050004226A1 (en) * 1998-12-10 2005-01-06 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
AU3713600A (en) 1999-03-01 2000-09-21 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
US6693135B2 (en) * 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6323241B1 (en) * 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US7105571B2 (en) * 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
KR100402334B1 (ko) * 2000-06-23 2003-10-22 환인제약 주식회사 알프로스타딜 외용제
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
KR100373540B1 (ko) * 2000-09-20 2003-02-25 최한곤 프로스타글란딘 ｅ1용 요도좌제 조성물
KR100810404B1 (ko) * 2001-12-18 2008-03-04 환인제약 주식회사 알프로스타딜 알킬 에스테르를 함유하는 외용제 조성물
US20050159485A1 (en) * 2002-01-04 2005-07-21 Jost-Price Edward R. Combinations for the treatment of immunoinflammatory disorders and proliferative skin diseases
KR20040082431A (ko) * 2002-02-15 2004-09-24 넥스메드 홀딩스 인코포레이티드 발기기능장애를 치료하기 위한 프로스타글란딘 조성물
WO2003092617A2 (en) * 2002-05-03 2003-11-13 Combinatorx, Incorporated Combinations for the treatment of inflammatory skin disorders
WO2004007786A2 (en) * 2002-07-17 2004-01-22 Liquidmetal Technologies Method of making dense composites of bulk-solidifying amorphous alloys and articles thereof
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US6841574B2 (en) * 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
CN1774237A (zh) * 2003-03-21 2006-05-17 尼克美制药控股有限公司 前列腺素组合物及其促进血管生成的方法
CA2519707A1 (en) * 2003-03-21 2004-10-07 Nexmed (Holdings), Inc. Prostaglandin compositions for the treatment of erectile dysfunction
DK2106805T3 (da) * 2003-03-21 2011-08-15 Nexmed Holdings Inc Antifungal neglelak og anvendelsesmetode
EP1608378A1 (en) * 2003-04-02 2005-12-28 Nexmed (Holdings), Inc. Prostaglandin compositions and their use for the treatment of vasospasm
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
EP2420241A1 (en) * 2004-04-19 2012-02-22 Strategic Science & Technologies, LLC Transdermal delivery of beneficial substances effected by a hostile biophysical environment
AU2012201048B2 (en) * 2004-04-19 2013-06-06 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
JP2007532697A (ja) 2004-04-19 2007-11-15 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー 局所的血流増大の有益な効果
US20050276865A1 (en) * 2004-05-20 2005-12-15 Servet Buyuktimkin Peroxide compounds for the prevention and treatment of sexual dysfunction in humans
GB0417401D0 (en) * 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
RS52671B (sr) 2005-10-12 2013-06-28 Unimed Pharmaceuticals Llc Poboljšani gel testosterona i postupak korišćenja
US8358785B2 (en) * 2006-05-30 2013-01-22 Siemens Audiologische Technik Gmbh Hearing system with wideband pulse transmitter
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
CA2739376A1 (en) 2008-10-03 2010-04-08 Nexmed Holdings, Inc. Stabilized composition for treating psoriasis
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
EP2445493A1 (en) 2009-06-24 2012-05-02 Strategic Science & Technologies, LLC Topical composition containing naproxen
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
CN102481275B (zh) 2009-06-24 2014-07-23 战略科学技术有限公司 含有布洛芬的表面组合物
CN102858158A (zh) * 2010-05-04 2013-01-02 尼克美控股公司 小分子治疗剂的组合物
CN103237785A (zh) * 2010-09-24 2013-08-07 尼克美控股公司 增强的经颊药物递送系统和组合物
CN103442723A (zh) 2010-12-29 2013-12-11 战略科学与技术有限责任公司 治疗变态反应和其它适应症的系统和方法
EP2658551B1 (en) 2010-12-29 2020-07-01 Strategic Science & Technologies, LLC Treatment of erectile dysfunction and other indications
WO2012139033A1 (en) 2011-04-07 2012-10-11 Nexmed Holdings, Inc. Methods and compositions for treating raynaud's disease
ITRM20120036A1 (it) * 2012-02-02 2013-08-03 Robert Davis Steigerwalt Jr Applicazione transdermica di prostaglandina e1 per il trattamento dell¿ischemia oculare.
WO2015172102A1 (en) * 2014-05-09 2015-11-12 Nexmed Holdings, Inc. Treating female sexual arousal disorder and related symptoms

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5948409A (ja) * 1982-09-10 1984-03-19 Teikoku Seiyaku Kk 矯正的歯牙移動促進剤
DK243084A (da) * 1983-05-26 1984-11-27 Takeda Chemical Industries Ltd Perkutane farmaceutiske praeparater til udvortes brug
GB8416638D0 (en) * 1984-06-29 1984-08-01 Beecham Group Plc Topical treatment and composition
US4732892A (en) * 1985-07-12 1988-03-22 American Home Products Corporation L-α-amino acids as transdermal penetration enhancers
US4771004A (en) * 1986-08-29 1988-09-13 Iprx, Inc. Method for in vitro determination of transdermal absorption
US4808414A (en) * 1986-09-29 1989-02-28 Nelson Research & Development Co. Amide penetration enhancers for transdermal delivery of systemic agents
US5219885A (en) * 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
US4865848A (en) * 1987-02-26 1989-09-12 Alza Corporation Skin permeation enhancer compositions using sucrose esters
EP0302147A1 (en) * 1987-08-03 1989-02-08 The Procter & Gamble Company Topical tanning compositions
US5082866A (en) * 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
US4980378A (en) * 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
US5534260A (en) * 1989-02-23 1996-07-09 University Of Utah Percutaneous drug delivery system
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
JP3202777B2 (ja) * 1992-01-24 2001-08-27 リンテック株式会社 経皮吸収促進剤及びテープ製剤
US5380760A (en) * 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
ATE399004T1 (de) * 1993-12-13 2008-07-15 Avanir Pharmaceuticals Formulierungen aus c-20 bis c-28 alkoholen und saccharoseestern
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery

Also Published As

Publication number Publication date
JP2002544240A (ja) 2002-12-24
DE69919594T2 (de) 2005-09-15
CA2309165A1 (en) 1999-05-14
HK1034678A1 (en) 2001-11-02
ATE273714T1 (de) 2004-09-15
DE69919594D1 (de) 2004-09-23
AU757086B2 (en) 2003-01-30
JP4491560B2 (ja) 2010-06-30
HUP0201145A3 (en) 2004-05-28
KR20020012218A (ko) 2002-02-15
EP1178833B1 (en) 2004-08-18
ES2224661T3 (es) 2005-03-01
WO2000069469A1 (en) 2000-11-23
TR200002158T2 (tr) 2000-11-21
EP1178833A1 (en) 2002-02-13
HK1044289B (en) 2005-01-07
CN1284862A (zh) 2001-02-21
DK1178833T3 (da) 2004-11-22
JP2001521886A (ja) 2001-11-13
CN1354677A (zh) 2002-06-19
ES2338389T3 (es) 2010-05-06
HK1044289A1 (en) 2002-10-18
ATE455535T1 (de) 2010-02-15
IL135914A0 (en) 2001-05-20
CN1191060C (zh) 2005-03-02
CA2373821C (en) 2003-10-07
DK1028708T3 (da) 2010-05-03
TW443933B (en) 2001-07-01
KR100462442B1 (ko) 2004-12-17
IL146470A (en) 2010-12-30
WO1999022714A1 (en) 1999-05-14
EP1028708A4 (en) 2006-01-18
PT1178833E (pt) 2004-11-30
HU230300B1 (hu) 2015-12-28
KR100576986B1 (ko) 2006-05-10
BR9917299A (pt) 2002-07-09
EP1028708B1 (en) 2010-01-20
IL146470A0 (en) 2002-07-25
MXPA01011560A (es) 2002-06-04
EP1028708A1 (en) 2000-08-23
KR20010031836A (ko) 2001-04-16
HUP0201145A2 (hu) 2002-12-28
CA2373821A1 (en) 2000-11-23
DE69841463D1 (de) 2010-03-11
BR9813945A (pt) 2002-01-22
US6046244A (en) 2000-04-04
AU3989199A (en) 2000-12-05
CN1195523C (zh) 2005-04-06

Similar Documents

Publication Publication Date Title
CA2373821A1 (en) Topical compositions for prostaglandin e1 delivery
PT1255552E (pt) Composicoes de prostaglandina para o tratamento da disfuncao erectil masculina
US8603519B2 (en) Topical delivery of L-arginine to cause beneficial effects
HU229602B1 (en) Prostaglandin compositions and their use for preparation of medicaments sutable for treatment of male erectile dysfunction
TR200202308T2 (tr) Prostaglandin E1 içeren tropikal bileşimler
PT814796E (pt) Uso de um farmaco r-aine numa composicao protectora para o tratamento do cancro colorectal
ATE391495T1 (de) Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
NO934107D0 (no) Penetrasjonsfremmende substans
KR900005974A (ko) 남성의 성기능 장애 치료제
SE9601665D0 (sv) Biologically active composition
TR200000890T2 (tr) Topik ilacın üretilmesi için -amino levülozik asidin kullanılması
IE790098L (en) Solvent vehicle
US6897239B1 (en) Use of misoprostol and/or metabolites of misoprostol for treating sexual dysfunction in women
HU223204B1 (hu) Aldehidet és alumíniumvegyületet tartalmazó gyógyszerkészítmények
IT1262960B (it) Composizioni farmaceutiche somministrabili per via intranasale contenenti calcitonina quale principio attivo.